Grit Biotechnology Completes Series A+ Financing to Accelerate Development of its Tumor Infiltrating Lymphocyte (TIL) Therapy Pipeline
July 15, 2021 10:00 ET
|
GRIT Biotechnology
SHANGHAI, China, July 15, 2021 (GLOBE NEWSWIRE) -- Grit Bio, a leading cell therapy company developing Tumor Infiltrating Lymphocytes (TIL) therapies, today announced the closing of a Series A+...